Navigation Links
Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
Date:6/22/2011

SAN DIEGO, June 22, 2011 /PRNewswire/ -- Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody drug conjugate (ADC) programs at five upcoming scientific conferences. The presentations will include data obtained from recent xenograft studies comparing Ambrx ADCs with those created using other technologies.

"Ambrx technology has been clinically validated as safe and efficacious for creating PEGylated proteins, and we have recently focused our efforts on creating site-specific conjugates of antibodies with best-in-class potential," Dr. Cho said. "Preclinical data obtained from partnered and unpartnered programs show us that the application of our technology to creating ADCs has tremendous potential. We look forward to presenting this promising data to the scientific community over the coming months."

At the IBC Life Sciences' Next Generation Protein Therapeutics Summit in San Francisco, Dr. Cho will deliver a presentation titled "Synthetic Biology Applied to Biotherapeutics" at 1:30 p.m. PDT on June 22, 2011.

At the American Chemical Society's 242nd National Meeting in Denver, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry with an Expanded Genetic Code" at 9 a.m. MDT on August 29, 2011.

At the Cambridge Healthtech Institute's PEGs Europe conference in Hannover, Germany, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry Applied to Antibody Drug Conjugates" at 3:05 p.m. CEST on October 11, 2011.

At the World Antibody Drug Conjugate Summit in San Francisco, Dr. Cho will deliver a presentation titled "Optimized Antibody Drug Conjugates with an Expanded Genetic Code" at 10 a.m. PDT on October 27, 2011.

Dr. Cho will also deliver a presentation at the IBC Life Sciences' Empowered Antibody Therapies Conference, held August 1-3, 2011, in San Francisco.

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its broad biologics platform to create best-in-class therapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx is developing several product candidates in collaboration with Eli Lilly and Company, including a Phase 3 compound expected to be launched commercially in 2013. The company has validated its biologics platform through additional partnerships with Pfizer and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology
2. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
3. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
4. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
5. Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference
6. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
7. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
8. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
9. Simulated Environment Concepts to Present at National Eagles and Angels Association New York Meeting
10. Radiation Therapy Services Holdings, Inc. to Present at the Wells Fargo Securities 2011 Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... COPENHAGEN, Denmark , March 23, 2017 ... utilizes its innovative TransCon technology to address significant unmet ... company will host a conference call and webcast on ... of the Endocrine Society in Orlando, Florida ... rare disease pipeline candidates (TransCon Growth Hormone, TransCon PTH ...
(Date:3/23/2017)... /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or ... announces that AB Laboratories Inc. ("AB Labs") has successfully ... under the Access to Cannabis for Medical Purposes Regulations ... The facility, which was licensed for ... operating at half capacity, with full production capacity scheduled ...
(Date:3/23/2017)... , March 23, 2017 ... consolidated vendor landscape with the top five players ... in 2015. These companies are Stryker Sustainability Solutions, ... Health Services, Inc., and VANGUARD AG. Despite the ... devices market is witnessing the prevalence of fierce ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 2017 , ... The StayWell Company announced today that it ... StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, and ... programs for the delivery and improvement of disease management and that meet or ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... training program owned and organized by HMP Communications Holdings, LLC, today announced that ... physicians within its nationwide network of wound centers interested in becoming Certified Wound ...
(Date:3/23/2017)... Collins, CO (PRWEB) , ... March 23, 2017 ... ... firm serving the families and businesses of the greater Fort Collins area, has ... campaign in their ongoing community involvement program. Donations to this worthy cause may ...
(Date:3/23/2017)... York City (PRWEB) , ... March 23, 2017 , ... ... last fall, FaceCradle , the most-funded travel pillow in crowdfunding history, ... speed delivery of its wildly popular travel innovation to Americans. , “We’re excited to ...
(Date:3/23/2017)... ... ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... 43rd President of the United States of America: George W. Bush , ... of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw ...
Breaking Medicine News(10 mins):